How do you utilize CDK 4/6 inhibitors in metastatic ER+ HER2+ breast cancer?

The benefit of adding a CDK4/6 inhibitor to the arsenal of treatment options in the hormone receptor (HR) and HER2-positive metastatic breast cancer setting is unknown. We are trying to answer this question through clinical trials, such as the multi-center Randomized, Open Label, Clinical Study of t...